- Règles de publication:
test Les acteurs essentiels d'une étude clinique sont l'investigateur coordinateur, les investigateurs, les membres de l'équipe salariée de l'IFCT et les membres des conseils d'administration et scientifiques qui tous collaborent à des degrés divers depuis la conception de l'essai jusqu'à l'écriture finale des résultats.
L'investigateur coordinateur a le choix entre la première et la dernière place. Il doit dans les deux cas avoir largement participé à la conception de l'essai, aux inclusions et à la rédaction de l'article.
S'il choisit la première place la dernière revient au président, à l'un des secrétaires ou à l'un des autres membres élu du Conseil d'administration (CA) ou au secrétaire du Conseil scientifique (CS). Celui-ci doit être choisi sur sa participation à la conception de l'essai, aux inclusions et à la rédaction de l'article. En cas de difficultés sur le choix de cette personne c'est un vote vote à bulletin secret du CA qui tranchera.
S'il choisit la dernière place l'avant dernière revient au président, à l'un des secrétaires ou à l'un des autres membres élu du CA ou au secrétaire du CS dans les mêmes conditions, à moins que celui-ci prenne la première place si en accord avec l'investigateur coordinateur il rédige l'article. En cas de difficultés sur le choix de cette personne, c'est un vote à bulletin secret du CA qui tranchera.
Les investigateurs apparaissent par ordre d'inclusion de patients éligibles. Tous les autres investigateurs doivent apparaitre sur une liste en appendice.
Deux membres de la même équipe ne peuvent pas signer le même article sauf si l'un d'entre eux apparait en tant qu'investigateur coordinateur ou membre du CA ou secrétaire du CS signataire en tant que tel en première, dernière ou avant dernière place.
Les membres de l'équipe salariée de l'IFCT jouent un rôle essentiel dans les études cliniques. A ce titre ceux qui sont impliqués dans la conception de l'essai, sa gestion ou à la rédaction de l'article doivent apparaitre systématiquement dans les remerciements ou comme signataires. Leurs noms sera indiqué par le directeur à l'investigateur principal. S'ils apparaissent comme signataires ils ne doivent pas figurer dans les 6 premières ou les 2 dernières places. Leur nombre ne doit pas excéder deux si le nombre de signataires est supérieur à 10, 1 s'il est égal ou inférieur à 10.
Si un statisticien universitaire a collaboré à l'élaboration et au traitement des données d'un essai, il pourra signer en accord avec l'investigateur principal à une place définie entre eux de façon consensuelle (en général la 3ème ou 4éme place).
En aucun cas quelqu'un ne pourra réclamer une signature au titre d'avoir soigné un malade pour des soins courants qui ne relèvent pas de la recherche.
L'ensemble des investigateurs (1 par centre investigateur de l'IFCT) sera listé à la suite de chaque article dans un tableau pouvant aussi comprendre anatomo-pathologiste, chirurgien, radiothérapeute du centre en fonction de l'article, afin que cette citation induise une occurrence Medline .
Pour les études ancillaires (biologique, radiologique ou autre...), en cas d'article ou abstract à 10 signatures maximum, l'investigateur coordinateur de l'étude biologique a le choix entre la première et la dernière place. Il doit dans les deux cas avoir largement participé à la conception de l'essai, à son financement, aux inclusions et à la rédaction de l'article. Les règles ci-dessus s'appliquent pour la dernière place s'il choisit la première place. L'avant-dernière place peut revenir au chef du laboratoire de recherche ayant eut la contribution la plus décisive dans l'étude. L'ante-pénultième place peut revenir à l'Investigateur principal de l'étude clinique si ce n'est pas l'IP de l'étude biologique. Les quatre premières places pourront être occupées par les scientifiques ou médecins, membres ou non de l'IFCT, ayant contribué le plus à l'étude ancillaire, dont, le cas échéant, le statisticien universitaire sur proposition de l'IP et du bureau du CA et validation par le CA. Si 10 signataires maximum, 3 à 4 places centrales seront réservées aux 3 à 4 meilleurs inclueurs (au sens ayant le plus contribué en termes de prélèvements anatomo-pathologiques) cliniciens. En cas d'articles avec 20 signatures, 2 à 3 places seront réservées pour les pathologistes ayant le plus contribué à l'étude (soit dans la collecte de spécimen, soit dans la relecture du panel ana-path de l'IFCT). L'ensemble des labo de biologie ayant participé à l'étude devra être représenté par un signataire, les reste des places de signataires devant être attribués à des cliniciens selon les règles ci-dessus, en incluant 1 membre de l'équipe permanent de l'IFCT ayant le plus contribué à l'étude (décision de l'IC + Directeur+ Président), ainsi que l'IP de l'étude clinique.
Tous les articles devront porter à la fin de la liste des signataires la mention "..on behalf of IFCT" et comprendre dans leur titre l'acronyme IFCT-XXYY de l'essai clinique dont l'étude ancillaire est issue.
L’IFCT peut être amené à se faire aider pour la mise en forme en anglais d’un article mais ne délègue jamais la rédaction proprement dite à une agence ou à l'industrie.
Ces règles ont été élaborées et validées par le Conseil d'Administration de l’IFCT en septembre 2010 - Icone font awsome: test
STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial
- Etude concernée: IFCT-0801
- Journal / Conference: Lung Cancer
- Année / Year: 2024
- PMID: 38428265
- Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/38428265/
Osimertinib chez les patients atteint d’un cancer bronchique non à petites cellules (CBNPC) muté EGFR présentant des métastases cérébrales ou leptoméningées : résultats de l’étude IFCT-1804 ORBITAL
- Etude concernée: IFCT-1804
- Journal / Conference: CPLF
- Année / Year: 2024
- PMID: Poster session
- Lien vers la publication: https://www.sciencedirect.com/science/article/abs/pii/S1877120323003427
Traitement des cancers bronchiques à petites cellules (CBPC) : Intérêt des études en vie réelle. A propos de 2 études de l’IFCT : IFCT-1905 Clinatezo et IFCT-2105 Lurbiclin
- Etude concernée: IFCT-1905
- Journal / Conference: CPLF
- Année / Year: 2024
- PMID: Poster session
- Lien vers la publication: https://www.sciencedirect.com/science/article/abs/pii/S1877120323003397
Efficacité et tolérance du sotarasib chez les patients porteurs d’un cancer bronchique non à petites cellules avec une mutation KRAS G12C : résultats de l’étude en vie réelle IFCT-2102 Lung KG12Ci
- Etude concernée: IFCT-2102
- Journal / Conference: CPLF
- Année / Year: 2024
- PMID: Oral abstract
- Lien vers la publication: https://www.researchgate.net/publication/377251355_Efficacite_et_tolerance_du_sotarasib_chez_les_patients_porteurs_d'un_cancer_bronchique_non_a_petites_cellules_avec_une_mutation_KRAS_G12_C_resultats_de_l'etude_en_vie_reelle_IFCT-2102_Lung_KG12Ci
Essai randomisé contrôlé comparant l’association pembrolizumab plus chimiothérapie à la chimiothérapie seule dans le mésothéliome pleural avancé, non prétraité (essai IND. 227, IFCT-1901)
- Etude concernée: IFCT-1901
- Journal / Conference: CPLF
- Année / Year: 2024
- PMID: Oral abstract
- Lien vers la publication: https://www.em-consulte.com/article/1640741/article/essai-randomise-controle-comparant-l-association-p
Real-world effectiveness and safety of sotorasib in patients with KRAS G12C mutated metastatic non-small cell lung cancer (NSCLC): Results of the IFCT-2102 Lung KG12Ci study
- Etude concernée: IFCT-2102
- Journal / Conference: ESMO
- Année / Year: 2023
- PMID: Poster session
- Lien vers la publication: https://www.ifct.fr/images/IFCT-2102_LungKG12Ci_ESMO_2023_Poster_V1.0_10OCT2023.pdf
Osimertinib in patients with EGFR-mutated NSCLC and leptomeningeal or brain metastases: Results of the IFCT-1804 ORBITAL trial
- Etude concernée: IFCT-1804
- Journal / Conference: ESMO
- Année / Year: 2023
- PMID: Poster session
- Lien vers la publication: https://www.ifct.fr/images/IFCT-1804_poster_v1.0_20231012.pdf
Impact of a minimal versus CT-scan-based follow-up on patient-reported outcomes for completely resected non-small cell lung cancer (NSCLC) in phase III IFCT-0302 trial
- Etude concernée: IFCT-0302
- Journal / Conference: ESMO
- Année / Year: 2023
- PMID: Oral abstract
- Lien vers la publication: https://www.annalsofoncology.org/article/S0923-7534(23)01576-4/pdf
Radiotherapy boost to 74 Gy based on FDG-PET at 42 Gy of radiochemotherapy (RCT) in patients with inoperable stage III non-small cell lung cancer (RTEP7-IFCT-1402): a prospective multicentre, open-label, randomised, controlled trial
- Etude concernée: IFCT-1402
- Journal / Conference: ESMO
- Année / Year: 2023
- PMID: Oral abstract
- Lien vers la publication: https://www.annalsofoncology.org/action/showPdf?pii=S0923-7534%2823%2901605-8
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial
- Etude concernée: IFCT-1901
- Journal / Conference: The Lancet
- Année / Year: 2023
- PMID: 37931632
- Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/37931632/
- PDF: Lancet.pdf
Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study
- Etude concernée: IFCT-1905
- Journal / Conference: Lung Cancer
- Année / Year: 2023
- PMID: 37757576
- Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/37757576/
- PDF: 1-s2.0-S0169500223009170-main.pdf
VEGFR2 and CD34 expression associated with longer survival in patients with pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trial
- Etude concernée: MAPS
- Journal / Conference: Lung Cancer
- Année / Year: 2023
- PMID: 37393757
- Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/37393757/
IFCT-2105 lurbiclin real-world effectiveness and treatment sequences in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) who received lurbinectedin as part of the French Early Access Program (EAP-ATU).
- Etude concernée: IFCT-2105
- Journal / Conference: ASCO
- Année / Year: 2023
- PMID: Poster session
- Lien vers la publication: https://meetings.asco.org/abstracts-presentations/223135
- PDF: LURBICLIN_poster_ASCO_V3_12MAY2023.pptx_002.pdf
Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.
- Etude concernée: IFCT-1905
- Journal / Conference: ASCO
- Année / Year: 2023
- PMID: Poster session
- Lien vers la publication: https://meetings.asco.org/abstracts-presentations/223134
- PDF: IFCT-1905_CLINATEZO_Poster_ASCO_2023.pdf
Nivolumab (Nivo) plus ipilimumab (Ipi) 6-month treatment versus continuation in patients with advanced non-small-cell-lung cancer (aNSCLC): 3-year results of the IFCT-1701 DICIPLE phase 3 trial
- Etude concernée: IFCT-1701
- Journal / Conference: ASCO
- Année / Year: 2023
- PMID: Poster session
- Lien vers la publication: https://meetings.asco.org/abstracts-presentations/226548
IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.
- Etude concernée: IFCT-1901
- Journal / Conference: ASCO
- Année / Year: 2023
- PMID: Oral abstract
- Lien vers la publication: https://meetings.asco.org/abstracts-presentations/218833
Association of ctDNA tumor fraction with survival in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/IFCT1301 trial.
- Etude concernée: IFCT-1301
- Journal / Conference: ASCO
- Année / Year: 2023
- PMID: Oral abstract
- Lien vers la publication: https://meetings.asco.org/abstracts-presentations/222957
Capmatinib chez les patients porteurs d’un cancer bronchique non à petites cellules avec une mutation MET exon 14 : résultats de l’étude en vraie vie IFCT-2104 CapmATU
- Etude concernée: IFCT-2104
- Journal / Conference: CPLF
- Année / Year: 2023
- PMID: Oral session
- Lien vers la publication: https://abstracts.splf.fr/?raw=1&abstract=54&congres=61
Etude de phase II-III randomisée (IFCT-1701 DICIPLE), comparant une continuation du doublet d’immunothérapie Nivolumab-Ipilimumab jusqu’à progression à une observation chez des patients avec un Cancer Bronchique Non à Petites Cellules (CBNPC) métastatique
- Etude concernée: IFCT-1701
- Journal / Conference: CPLF
- Année / Year: 2023
- PMID: Oral session
- Lien vers la publication: https://abstracts.splf.fr/?raw=1&abstract=45&congres=61
Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome
- Etude concernée: IFCT-1301
- Journal / Conference: Lung Cancer
- Année / Year: 2022
- PMID: 35609409
- PDF: SAFIR02.pdf
Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung Trial
- Etude concernée: IFCT-1301
- Journal / Conference: Clinical cancer research
- Année / Year: 2022
- PMID: 35802649
- PDF: SAFIR02_CCR2022.pdf
Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)
- Etude concernée: IFCT-1601
- Journal / Conference: The Journal for Immunotherapy of Cancer
- Année / Year: 2022
- PMID: 36270733
- Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/36270733/
- PDF: e005636.full.pdf
Increased incidence of thymic epithelial tumors during COVID-19 pandemic: A retrospective analysis from the French RYTHMIC network
- Etude concernée: IFCT-1104
- Journal / Conference: ESMO
- Année / Year: 2022
- PMID: Poster
- Lien vers la publication: https://cslide.ctimeetingtech.com/esmo2022/attendee/confcal_2/presentation/list?q=rythmic
Capmatinib for METex14 non-small cell lung cancer patients: results of the real-world study IFCT-2104 CapmATU
- Etude concernée: IFCT-2104
- Journal / Conference: ESMO
- Année / Year: 2022
- PMID: Poster
- Lien vers la publication: https://cslide.ctimeetingtech.com/esmo2022/attendee/confcal_2/presentation/list?q=CapmATU&c=pt
Nivolumab (Nivo) plus Ipilimumab (Ipi) 6-months treatment versus continuation in patients with advanced Non-Small-Cell-Lung Cancer (aNSCLC): results of the randomized IFCT-1701 phase 3 trial
- Etude concernée: IFCT-1701
- Journal / Conference: ESMO
- Année / Year: 2022
- PMID: Oral session
- Lien vers la publication: https://oncologypro.esmo.org/meeting-resources/esmo-congress/nivolumab-nivo-plus-ipilimumab-ipi-6-months-treatment-versus-continuation-in-patients-with-advanced-non-small-cell-lung-cancer-ansclc-result
Outcome of Patients With Resected Early-Stage Non-Small Cell Lung Cancer and EGFR mutations: Results from the IFCT Biomarkers France Study
- Etude concernée: BF
- Journal / Conference: Clinical Lung cancer
- Année / Year: 2022
- Lien vers la publication: https://www.sciencedirect.com/science/article/pii/S1525730422001978
- PDF: 1-s2.0-S1525730422001978-main.pdf
Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial
- Etude concernée: IFCT-0302
- Journal / Conference: The Lancet Oncology
- Année / Year: 2022
- PMID: 35964621
- Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/35964621/
- PDF: Article.pdf
Availability of results of academic randomized trials involving cooperative groups in oncology in France: A systematic search of clinical trial registries
- Journal / Conference: Journal of Cancer Policy
- Année / Year: 2022
- PMID: 35779787
- Lien vers la publication: https://www.sciencedirect.com/science/article/pii/S2213538322000261?dgcid=author
- PDF: 1-s2.0-S2213538322000261-main.pdf
A phase II randomized, open-labelled, multicenter study of safety and efficacy of combination brigatinib and carboplatin-pemetrexed therapy or brigatinib monotherapy as first-line treatment in patients with advanced ALK-positive non–small cell lung cancer
- Etude concernée: IFCT-2101
- Journal / Conference: ASCO
- Année / Year: 2022
- PMID: Poster session
- Lien vers la publication: https://meetings.asco.org/abstracts-presentations/213183
The Lung ART adjuvant radiotherapy phase 3 randomized trial: Impact of quality of resection in stage IIIAN2 patients
- Etude concernée: IFCT-0503
- Journal / Conference: ASCO
- Année / Year: 2022
- PMID: Poster session
- Lien vers la publication: https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.8522?af=R
Efficacy of dabrafenib-trametinib combination in BRAF V600E-mutated metastatic non–small cell lung cancer: Results of the IFCT-2004 BLaDE cohort.
- Etude concernée: IFCT-2004
- Journal / Conference: ASCO
- Année / Year: 2022
- PMID: Poster session
- Lien vers la publication: https://meetings.asco.org/abstracts-presentations/208898
Impact of Anti PD-1 Immunotherapy on HIV Reservoir and Anti-Viral Immune Responses in People Living with HIV and Cancer
- Etude concernée: IFCT-1602
- Journal / Conference: Cells
- Année / Year: 2022
- PMID: 35326466
- Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/35326466/
- PDF: cells-11-01015-v2.pdf
Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancer
- Etude concernée: IFCT-0803
- Journal / Conference: Cancer/Radiothérapie
- Année / Year: 2022
- PMID: 35260342
- Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/35260342/
- PDF: 1-s2.0-S127832182200035X-main.pdf
A Defect of Amphiregulin Release Predicted Longer Survival Independently of YAP Expression in Patients with Pleural Mesothelioma in the IFCT-0701 MAPS Phase 3 Trial
- Etude concernée: MAPS
- Journal / Conference: International Journal of Cancer
- Année / Year: 2022
- PMID: 35262190
- Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/35262190/
Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study
- Etude concernée: IFCT-1803
- Journal / Conference: ESMO open
- Année / Year: 2022
- PMID: 35227966
- Lien vers la publication: https://linkinghub.elsevier.com/retrieve/pii/S2059-7029(22)00039-4
- PDF: PIIS2059702922000394.pdf
Lorlatinib for advanced anaplastic lymphoma kinase–positive non–small cell lung cancer: Results of the IFCT-1803 LORLATU cohort
- Etude concernée: IFCT-1803
- Journal / Conference: European Journal of Cancer
- Année / Year: 2022
- PMID: 35278825
- Lien vers la publication: https://www.sciencedirect.com/science/article/pii/S0959804922000417?dgcid=coauthor
- PDF: LORLATU.EJC.042022.pdf
La réponse pathologique est un facteur pronostique indépendant de survie globale (SG) et sans récidive (SSR) après durvalumab en néoadjuvant dans les cancers bronchiques non à petites cellules (CBNPC) résécables dans l'essai de phase 2 IFCT-1601 IONESCO
- Etude concernée: IFCT-1601
- Journal / Conference: CPLF
- Année / Year: 2022
- PMID: Oral abstract
- Lien vers la publication: https://www.sciencedirect.com/science/article/abs/pii/S1877120321006224
Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01
- Etude concernée: IFCT-0201
- Journal / Conference: European Journal of Cancer
- Année / Year: 2016
- PMID: 26689864
- Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/26689864/
- PDF: Induction_or_consolidation_chemotherapy.pdf
Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial
- Etude concernée: IFCT-1703
- Journal / Conference: Journal of Clinical Oncology
- Année / Year: 2022
- PMID: 35073148
- Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/35073148/
Post-Discontinuation Treatments in IFCTGFPC-0701 MAPS Trial: Real-World Effectiveness of 2nd-Line (2L) Treatments for Mesothelioma
- Etude concernée: MAPS
- Journal / Conference: WCLC
- Année / Year: 2019
- PMID: Oral abstract
- Lien vers la publication: https://www.jto.org/article/S1556-0864(19)31215-8/fulltext
Outcomes of thymic epithelial tumors (TETs) with pleural metastases: Real-world insight from RYTHMIC.
- Etude concernée: IFCT-1104
- Journal / Conference: ASCO
- Année / Year: 2021
- PMID: Poster
- Lien vers la publication: https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.8578
Minimal residual disease (MRD) in patients with resected stage I NSCLC: Results of the prospective adjuvant IFCT-0703 trial
- Journal / Conference: ASCO
- Année / Year: 2021
- PMID: Poster session
- Lien vers la publication: https://meetinglibrary.asco.org/record/198772/abstract
Combination of trastuzumab, pertuzumab and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 mutation: Final results from the IFCT-1703 R2D2 trial.
- Etude concernée: IFCT-1703
- Journal / Conference: ASCO
- Année / Year: 2021
- PMID: Poster discussion
- Lien vers la publication: https://meetinglibrary.asco.org/record/197365/abstract
Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: results of the IFCT-GFPC-1101 multicenter randomized phase III trial
- Etude concernée: IFCT-GFPC-1101
- Journal / Conference: Lung Cancer
- Année / Year: 2022
- PMID: 35051725
- Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/35051725/
IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer
Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART, IFCT 0503): an open-label, randomised, phase 3 trial
- Etude concernée: IFCT-0503
- Journal / Conference: The Lancet Oncology
- Année / Year: 2021
- Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/34919827/
- PDF: TLO_Jan2022_p104_114_A6_1233_LePechoux_DOE_003.pdf
Intergroupe francophone de cancérologie thoracique, Société de pneumologie de langue française, and Société d'imagerie thoracique statement paper on lung cancer screening
- Journal / Conference: Diagnostic and Interventional Imaging
- Année / Year: 2021
- PMID: 33648872
- Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/33648872/
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
- Etude concernée: STIMULI
- Journal / Conference: Annals of Oncology
- Année / Year: 2021
- PMID: 34562610
- Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/34562610/
- PDF: ETOP_STIMULI_Peters_Pujol_et_al.pdf
Pathological response is an independent factor of overall survival and disease-free survival after neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase 2 trial
- Etude concernée: IFCT-1601
- Journal / Conference: ESMO
- Année / Year: 2021
- PMID: Oral abstract
- Lien vers la publication: https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/pathological-response-is-an-independent-factor-of-overall-survival-and-disease-free-survival-after-neoadjuvant-durvalumab-in-resectable-non-small-c
An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected NSCLC and mediastinal N2 involvement: characterisation of PORT efficacy in Lung ART (IFCT-0503, UK NCRI, SAKK)
- Etude concernée: IFCT-0503
- Journal / Conference: ESMO
- Année / Year: 2021
- PMID: Oral abstract
- Lien vers la publication: https://www.annalsofoncology.org/article/S0923-7534(21)04004-7/fulltext
Nivolumab (nivo) ± Ipilimumab (ipi) in pre-treated Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (GCO-001 NIPINEC)
- Etude concernée: GCO-001
- Journal / Conference: ESMO
- Année / Year: 2021
- PMID: Proffered Paper session
- Lien vers la publication: https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/nivolumab-nivo-ipilimumab-ipi-in-pre-treated-patients-with-advanced-refractory-pulmonary-or-gastroenteropancreatic-poorly-differentiated-neu
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
- Etude concernée: MAPS
- Journal / Conference: The Lancet
- Année / Year: 2016
- PMID: 26719230
- Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/26719230/
- PDF: MAPS.Lancet.12.2015.pdf
Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial.
- Etude concernée: MAPS
- Journal / Conference: Clinical Cancer Research
- Année / Year: 2019
- PMID: 31175096
- Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/31175096/
Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trial
- Etude concernée: IFCT-1602
- Journal / Conference: Lung Cancer
- Année / Year: 2021
- Lien vers la publication: https://www.sciencedirect.com/science/article/abs/pii/S0169500221004116
Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA)
- Etude concernée: IFCT-1001
- Journal / Conference: Lung Cancer
- Année / Year: 2021
- PMID: 34016488
- Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/34016488/
First-line Afatinib plus Cetuximab for EGFR-mutant Non-small-cell Lung Cancer: Results from the Randomized Phase 2 IFCT-1503 ACE-Lung Study
- Etude concernée: IFCT-1503
- Journal / Conference: Clinical Cancer Research
- Année / Year: 2021
- PMID: 34031056
- Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/34031056/
- PDF: Ace_lung_CCR.pdf
Lung Cancer Screening by Low-Dose CT Scan: Baseline Results of a French Prospective Study
- Journal / Conference: Clinical Lung Cancer
- Année / Year: 2020
- PMID: 31982356
- Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/31982356/
[Vaccination against COVID-19 in patients with solid cancer: Review and point of view from a French oncology inter-group (CGO, TNCD, UNICANCER)]
- Journal / Conference: Bulletin du cancer
- Année / Year: 2021
- PMID: 33902918
- Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/33902918/
Surveillance After Curative-Intent Treatment for NSCLC : More to it Than Meets the Eye
- Etude concernée: IFCT-0302
- Journal / Conference: Journal of Thoracic Oncology
- Année / Year: 2021
Recommandations de l’Intergroupe francophone de cancérologie thoracique, de la Société de pneumologie de langue française et de la Société d’imagerie thoracique sur le dépistage du cancer bronchopulmonaire par tomodensitométrie à faible dose d’irradiation
- Journal / Conference: Revue des Maladies Respiratoires
- Année / Year: 2021
- PMID: 33637394
- Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/33637394/
Durvalumab (D) compared to maintenance chemotherapy (SoC) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): Results from the randomized SAFIR02 LUNG-IMMUNO tria
- Etude concernée: IFCT-1301
- Journal / Conference: ESMO
- Année / Year: 2020
- PMID: Poster
- Lien vers la publication: https://www.annalsofoncology.org/article/S0923-7534(20)41583-2/fulltext
Autoimmune diseases in centrally reviewed Thymic Epithelial Tumors (TET)
- Etude concernée: IFCT-1104
- Journal / Conference: ESMO
- Année / Year: 2020
- PMID: Poster
- Lien vers la publication: https://www.annalsofoncology.org/article/S0923-7534(20)41438-3/fulltext
IFCT-1602 CHIVA2 phase II trial: Nivolumab in previously treated HIV-patients with advanced nonsmall cell lung cancer (NSCLC)
- Etude concernée: IFCT-1602
- Journal / Conference: ESMO
- Année / Year: 2020
- PMID: Poster
- Lien vers la publication: https://www.annalsofoncology.org/article/S0923-7534(20)41699-0/abstract
Lorlatinib for advanced ROS1+ Non-Small Cell Lung Cancer (NSCLC): efficacy and safety data from IFCT1803 LORLATU Expanded Access Program (EAP) cohort
- Etude concernée: IFCT-1803
- Journal / Conference: ESMO
- Année / Year: 2020
- PMID: Poster
- Lien vers la publication: https://www.annalsofoncology.org/article/S0923-7534(20)41659-X/abstract
Efficacité et tolérance du lorlatinib en 2e ligne ou plus chez les patients, porteurs d’un cancer bronchique non à petites cellules (CBNPC) avancé ALK+, traités dans le cadre d’une autorisation temporaire d’utilisation (ATU), Etude LORLATU IFCT-1803
- Etude concernée: IFCT-1803
- Journal / Conference: CPLF
- Année / Year: 2021
- PMID: Poster
Efficacité et tolérance du lorlatinib en 2e ligne ou plus chez les patients, porteurs d’un cancer bronchique non à petites cellules (CBNPC) avancé ROS1+, traités dans le cadre d’une autorisation temporaire d’utilisation (ATU), Etude LORLATU IFCT-1803
- Etude concernée: IFCT-1803
- Journal / Conference: CPLF
- Année / Year: 2021
- PMID: Oral abstract
- Lien vers la publication: http://www.congres-pneumologie.fr/FrontOffice/FOProgramme/Abstract?siteName=w3t1303gzv&sessionId=4874&abstractNum=104
Première analyse de l’essai Lung ART (IFCT-0503, UK NCRI, SAKK)
- Etude concernée: IFCT-0503
- Journal / Conference: CPLF
- Année / Year: 2021
- PMID: Oral abstract
- Lien vers la publication: https://www.sciencedirect.com/science/article/abs/pii/S1877120320302093
Immunothérapie (durvalumab) néoadjuvante dans les cancers bronchiques non à petites cellules (CBNPC): résultats préliminaires de l'étude multicentrique IFCT-1601 IONESCO
- Etude concernée: IFCT-1601
- Journal / Conference: CPLF
- Année / Year: 2021
- PMID: Oral abstract
- Lien vers la publication: http://www.congres-pneumologie.fr/FrontOffice/FOProgramme/Abstract?siteName=w3t1303gzv&sessionId=4863&abstractNum=11
Driver Oncogenic Alterations and Indoor Radon in NSCLC Patients From the IFCT Biomarker Cohort: Bioradon France Study
- Etude concernée: BF
- Journal / Conference: WCLC
- Année / Year: 2021
- PMID: Poster
- Lien vers la publication: https://library.iaslc.org/conference-program?product_id=20&author=&category=&date=&session_type=&session=&presentation=&keyword=IFCT&cme=undefined&
Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab
- Etude concernée: IFCT-1603
- Journal / Conference: Journal of Clinical Medicine
- Année / Year: 2020
- PMID: 33261056
- Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/33261056/
Etude de phase II randomisée non comparative de l'anti-PD-L1 atézolizumab versus chimiothérapie comme traitement de deuxième ligne chez les patients atteints d'un cancer du poumon à petites cellules (CBPC) : résultats de l'essai IFCT-1603
- Etude concernée: IFCT-1603
- Journal / Conference: CPLF
- Année / Year: 2019
- PMID: Oral abstract
- Lien vers la publication: https://www.sciencedirect.com/science/article/abs/pii/S0761842518304194
IFCT-1702 IMPACT-SEPSIS Impact d’un événement infectieux significatif sur le pronostic des patients atteints d’un cancer bronchique non à petites cellules avancées traités par chimiothérapie de 1re ligne
- Etude concernée: IFCT-1702
- Journal / Conference: CPLF
- Année / Year: 2019
- PMID: Oral abstract
- Lien vers la publication: https://www.sciencedirect.com/science/article/abs/pii/S0761842518304212
Prevalence of Autoimmune Diseases in Thymic Epithelial Tumors (TET) Insights from RYTHMIC
- Etude concernée: IFCT-1104
- Journal / Conference: WCLC
- Année / Year: 2017
- PMID: Oral abstract
- Lien vers la publication: https://library.iaslc.org/search?search_keyword=rythmic
Recurrences and 2Nd Primary Cancers in the IFCT-0302 Trial Assessing a CT-Scan-Based Follow-Up after Lung Cancer Surgery
- Etude concernée: IFCT-0302
- Journal / Conference: WCLC
- Année / Year: 2017
- PMID: Oral abstract
- Lien vers la publication: http://library.iaslc.org/conference-program?product_id=7&author=&category=&date=&session_type=&session=&presentation=&keyword=IFCT&
IFCT-1502 CLINIVO: Real-Life Experience with Nivolumab in 600 Patients (Pts) with Advanced Non-Small Cell Lung Cancer (NSCLC)
- Etude concernée: IFCT-1502
- Journal / Conference: WCLC
- Année / Year: 2017
- PMID: Oral abstract
- Lien vers la publication: http://library.iaslc.org/conference-program?product_id=7&author=&category=&date=&session_type=&session=&presentation=&keyword=IFCT&
Clinical and biological characteristics of non-small cell lung cancer (NSCLC) harbouring EGFR mutation: Results of the nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
- Etude concernée: BF
- Journal / Conference: ESMO
- Année / Year: 2016
- PMID: Oral abstract
- Lien vers la publication: https://cslide.ctimeetingtech.com/library/esmo/browse/search/CMb#2z9460FR
Second or 3rd line Nivolumab (Nivo) versus Nivo plus Ipilimumab (Ipi) in Malignant Pleural Mesothelioma (MPM) patients: updated results of the IFCT-1501 MAPS2 randomized phase 2 trial.
- Etude concernée: IFCT-1501
- Journal / Conference: ESMO
- Année / Year: 2017
- PMID: Oral abstract
- Lien vers la publication: https://www.annalsofoncology.org/article/S0923-7534(20)39174-2/fulltext
Results of the phase III IFCT-0302 trial assessing minimal versus CT-scan-based follow-up for completely resected non-small cell lung cancer (NSCLC)
- Etude concernée: IFCT-0302
- Journal / Conference: ESMO
- Année / Year: 2017
- PMID: Oral abstract
- Lien vers la publication: https://www.annalsofoncology.org/article/S0923-7534(20)38535-5/fulltext
Maintenance chemotherapy versus follow-up after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced nonsmall cell lung cancer (NSCLC): IFCT-1201 MODEL randomised phase 3 trial
- Etude concernée: IFCT-1201
- Journal / Conference: ESMO
- Année / Year: 2018
- PMID: Oral abstract
- Lien vers la publication: https://www.annalsofoncology.org/article/S0923-7534(19)50459-8/fulltext
A randomized non-comparative phase II study of anti–PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 Trial
- Etude concernée: IFCT-1603
- Journal / Conference: ESMO
- Année / Year: 2018
- PMID: Oral abstract
- Lien vers la publication: https://www.annalsofoncology.org/article/S0923-7534(19)50049-7/abstract
Second/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: Long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on hyperprogression (HPD)
- Etude concernée: IFCT-1501
- Journal / Conference: ESMO
- Année / Year: 2019
- PMID: Oral abstract
- Lien vers la publication: https://www.annalsofoncology.org/article/S0923-7534(19)59971-9/fulltext
PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project
- Etude concernée: BF
- Journal / Conference: Lung Cancer
- Année / Year: 2020
- PMID: 33248711
- PDF: pTEN_Lung_cancer.pdf
The GCO-002 CACOVID-19 cohort: a French nationwide multicenter study of COVID-19 infected cancer patients and consequences on cancer management
- Etude concernée: GCO-002
- Journal / Conference: ESMO
- Année / Year: 2020
- PMID: Oral abstract
- Lien vers la publication: https://www.annalsofoncology.org/article/S0923-7534(20)41734-X/fulltext
Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy: Results from the ETOP/IFCT 4-12 STIMULI trial
- Etude concernée: STIMULI
- Journal / Conference: ESMO
- Année / Year: 2020
- PMID: Oral abstract
- Lien vers la publication: https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/consolidation-ipilimumab-and-nivolumab-vs-observation-in-limited-stage-sclc-after-chemo-radiotherapy-results-from-the-etop-ifct-4-12-stimuli-trial
An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients (pts) with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement. Primary end-point analysis of Lung ART (IFC
- Etude concernée: IFCT-0503
- Journal / Conference: ESMO
- Année / Year: 2020
- PMID: Presidentiel symposia
- Lien vers la publication: https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/an-international-randomized-trial-comparing-post-operative-conformal-radiotherapy-port-to-no-port-in-patients-with-completely-resected-non-smal
Neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC): Preliminary results from a multicenter study (IFCT-1601 IONESCO)
- Etude concernée: IFCT-1601
- Journal / Conference: ESMO
- Année / Year: 2020
- PMID: Oral abstract
- Lien vers la publication: https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/neoadjuvant-durvalumab-in-resectable-non-small-cell-lung-cancer-nsclc-preliminary-results-from-a-multicenter-study-ifct-1601-ionesco
Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC)
- Etude concernée: IFCT-0501
- Journal / Conference: ASCO
- Année / Year: 2010
- PMID: Oral (Plenary)
- Lien vers la publication: https://ascopubs.org/doi/abs/10.1200/jco.2010.28.18_suppl.2
Biomarker-driven access to crizotinib in ALK-, MET-, or ROS1-positive malignancies in adults and children: Feasibility of the French National Acsé Program
- Journal / Conference: ASCO
- Année / Year: 2014
- PMID: Poster
- Lien vers la publication: https://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.tps2647
National multidisciplinary tumor board (MTB): Report of the first 526 questions raised within RYTHMIC, the network for thymic malignancies in France.
- Journal / Conference: ASCO
- Année / Year: 2014
- PMID: Poster
- Lien vers la publication: https://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.7605
Phase II study of cetuximab, pemetrexed, cisplatin and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small cell lung cancer (NSCLC): Results of the IFCT-0803 trial
- Etude concernée: IFCT-0803
- Journal / Conference: ASCO
- Année / Year: 2014
- PMID: Poster discussion
Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: Results from the IFCT-0802 trial
- Etude concernée: IFCT-0802
- Journal / Conference: ASCO
- Année / Year: 2014
- PMID: Oral abstract
- Lien vers la publication: https://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.7505
Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial
- Etude concernée: MAPS
- Journal / Conference: ASCO
- Année / Year: 2015
- PMID: Oral abstract
- Lien vers la publication: https://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.7500
Pathological central review of 290 thymic epithelial tumors (TET) : The national network RYTHMIC experience.
- Etude concernée: IFCT-1104
- Journal / Conference: ASCO
- Année / Year: 2016
- PMID: Poster
- Lien vers la publication: https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.8568
A phase II study assessing the benefit of cisplatin re-introduction (stop and go strategy) in patients with advanced non-squamous non-small cell lung cancer (NSCLC) : The IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer).
- Etude concernée: IFCT-1102
- Journal / Conference: ASCO
- Année / Year: 2016
- PMID: Poster
- Lien vers la publication: https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.9077
Weekly paclitaxel plus bevacizumab versus docetaxel as second or third-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC): Results from the phase III study IFCT-1103 ULTIMATE
- Etude concernée: IFCT-1103
- Journal / Conference: ASCO
- Année / Year: 2016
- PMID: Oral abstract
- Lien vers la publication: https://ascopubs.org/doi/abs/10.1200/jco.2016.34.15_suppl.9005
IFCT-1001 CHIVA trial : A phase II study of carboplatin (Ca) plus pemetrexed (P) followed by P maintenance, as first-line therapy for human immunodeficiency virus (HIV)–associated advanced non-squamous non-small cell lung cancer (NS-NSCLC)
- Etude concernée: IFCT-1001
- Journal / Conference: ASCO
- Année / Year: 2016
- PMID: Poster
- Lien vers la publication: https://ascopubs.org/doi/10.1200/JCO.2016.34.15_suppl.9076
IFCT-GFPC-1101 trial: A multicenter phase III assessing a maintenance strategy determined by response to induction chemotherapy compared to continuation maintenance with pemetrexed in patients (pts) with advanced non-squamous (NSQ) NSCLC
- Etude concernée: IFCT-GFPC-1101
- Journal / Conference: ASCO
- Année / Year: 2017
- PMID: Oral abstract
- Lien vers la publication: https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.9003
Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.
- Etude concernée: IFCT-1501
- Journal / Conference: ASCO
- Année / Year: 2017
- PMID: Oral abstract
- Lien vers la publication: https://ascopubs.org/doi/abs/10.1200/jco.2017.35.18_suppl.lba8507
Impact on health-related quality of life of the addition of bevacizumab to cisplatin-pemetrexed in malignant pleural mesothelioma in the MAPS phase III trial
- Etude concernée: MAPS
- Journal / Conference: ASCO
- Année / Year: 2018
- PMID: Oral abstract
- Lien vers la publication: https://meetinglibrary.asco.org/record/160037/abstract
Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial
- Etude concernée: IFCT-1003
- Journal / Conference: ASCO
- Année / Year: 2018
- PMID: Poster
- Lien vers la publication: https://meetinglibrary.asco.org/record/161040/abstract
IFCT --French Intergroup of Thoracic Cancerology: presentation, protocols
- Journal / Conference: Cancer Radiothérapie
- Année / Year: 2001
- PMID: 11236545
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/11236545
Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer
- Journal / Conference: Journal of Clinical Oncology
- Année / Year: 2002
- PMID: 11773176
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/11773176
French clinical research in thoracic oncology
- Journal / Conference: Revue de Pneumologie Clinique
- Année / Year: 2004
- PMID: 15687994
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/15687994
Complete response following preoperative chemotherapy for resectable non-small cell lung cancer: accuracy of clinical assessment using the French trial database
- Journal / Conference: Chest
- Année / Year: 2005
- PMID: 16162741
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/16162741
Follow up of non small cell lung cancer. Should patients be followed up after surgery for non-small cell lung cancer and how?
- Journal / Conference: Revue des Maladies Respiratoires
- Année / Year: 2006
- PMID: 17268342
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/17268342
IFCT-0302 trial: Randomised study comparing two follow-up schedules in completely resected non-small cell lung cancer
- Etude concernée: IFCT-0302
- Journal / Conference: Revue des Maladies Respiratoires
- Année / Year: 2007
- PMID: 17519819
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/17519819
Standards, Options and Recommendations (SOR) for the Perioperative Treatment of Patients With Resectable and operable Non-Small Cell Lung Cancer (updated)
- Journal / Conference: Oncology
- Année / Year: 2007
What treatment for a patient of PS 2-3 with stage IV non-small cell lung cancer?
- Journal / Conference: Revue des Maladies Respiratoires
- Année / Year: 2007
- PMID: 18235404
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/18235404
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours
- Journal / Conference: Journal of Thoracic Oncology
- Année / Year: 2007
- PMID: 17762336
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/17762336
The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours
- Journal / Conference: Journal of Thoracic Oncology
- Année / Year: 2007
- PMID: 17762335
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/17762335
The IASLC Lung Cancer Staging Project: Proposals for Revision of the M Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification of Lung Cancer
- Journal / Conference: Journal of Thoracic Oncology
- Année / Year: 2007
- PMID: 17762334
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/17762334
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the T Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer
- Journal / Conference: Journal of Thoracic Oncology
- Année / Year: 2007
- PMID: 17607114
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/17607114
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the T Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer
- Journal / Conference: Journal of Thoracic Oncology
- Année / Year: 2007
- PMID: 17607114
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/17607114
Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01
- Etude concernée: IFCT-0001
- Journal / Conference: Journal of Clinical Oncology
- Année / Year: 2007
- PMID: 17761978
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/17761978
How to treat the relapse of NSCLC after surgery and chemotherapy? IFTC 0702 randomized phase III study
- Etude concernée: IFCT-0702
- Journal / Conference: Revue des Maladies Respiratoires
- Année / Year: 2008
- PMID: 18288059
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/18288059
Patient participation in thoracic cancer clinical trials
- Journal / Conference: Journal of Thoracic Oncology
- Année / Year: 2008
- PMID: 18166833
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/18166833
Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a r
- Etude concernée: IFCT-9901
- Journal / Conference: The Lancet Oncology
- Année / Year: 2009
- PMID: 19386548
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/19386548
IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype
- Etude concernée: 0401-EPIDEMIO
- Journal / Conference: Journal of Thoracic Oncology
- Année / Year: 2009
- PMID: 19574932
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/19574932
Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial
- Etude concernée: IFCT-0101
- Journal / Conference: Lung Cancer
- Année / Year: 2010
- PMID: 19879013
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/19879013
The role of pemetrexed in lung adenocarcinoma, mixed subtype with bronchioloalveolar carcinoma features
- Etude concernée: IFCT-0504
- Journal / Conference: Current drug Targets
- Année / Year: 2010
- PMID: 19839924
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/19839924
Management and outcome of French elderly patients with lung cancer: an IFCT survey
- Etude concernée: IFCT-0202
- Journal / Conference: Revue des Maladies Respiratoires
- Année / Year: 2010
- PMID: 20569874
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/20569874
Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study)
- Etude concernée: IFCT-0301
- Journal / Conference: Lung Cancer
- Année / Year: 2010
- PMID: 20400201
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/20400201
Update on nonsmall cell lung cancer
- Journal / Conference: European Respiratory Review
- Année / Year: 2010
- PMID: 20956190
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/20956190
Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib
- Journal / Conference: Lung Cancer
- Année / Year: 2010
- PMID: 19581016
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/19581016
Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01)
- Etude concernée: IFCT-9901
- Journal / Conference: Annals of Oncology
- Année / Year: 2011
- PMID: 21139020
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/21139020
A phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non squamous, non-small cell lung cancer (NSCLC)
- Etude concernée: IFCT-0803
- Journal / Conference: Revue des Maladies Respiratoires
- Année / Year: 2011
- PMID: 21277474
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/21277474
Pemetrexed re-challenge in pleural malignant mesothelioma: An option for a subset of patients initially treated with pemetrexed-platinum doublets in the first-line setting?
- Journal / Conference: Lung Cancer
- Année / Year: 2011
- PMID: 21277041
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/21277041
Prognostic and predictive biomarkers in non-small cell lung cancers. From conditioned registrations to routine molecular mapping of lung cancers: Methodological issues
- Journal / Conference: Presse Médicale
- Année / Year: 2011
- PMID: 21376511
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/21376511
Metastatic non-small cell lung cancer: Systemic treatment of patients aged 70 and over
- Etude concernée: IFCT-0501
- Journal / Conference: Presse Médicale
- Année / Year: 2011
- PMID: 21388776
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/21388776
Non-small cell lung carcinoma: Perspectives for the twenty-first century ?
- Journal / Conference: Presse Médicale
- Année / Year: 2011
- PMID: 21388779
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/21388779
Cross-Validation Study for Epidermal Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded Non-small Cell Lung Carcinoma Samples: A Total of 5550 Exons Sequenced by 15 Molecular French Laboratories (Evaluation of the EGFR Mutation Status for th
- Etude concernée: ERMETIC
- Journal / Conference: Journal of Thoracic Oncology
- Année / Year: 2011
- PMID: 21532509
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/21532509
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial
- Etude concernée: IFCT-0501
- Journal / Conference: The Lancet
- Année / Year: 2011
- PMID: 21831418
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/21831418
Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma
- Etude concernée: 0401-EPIDEMIO
- Journal / Conference: Journal Pathology
- Année / Year: 2011
- PMID: 21598249
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/21598249
Chemotherapy in elderly patients with advanced non-small cell lung cancer
- Journal / Conference: Lung Cancer
- Année / Year: 2011
- PMID: 21893363
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/21893363
Cost-effectiveness of three strategies for second-line erlotinib initiation in non small-cell lung cancer: the ERMETIC Study Part 3
- Etude concernée: ERMETIC
- Journal / Conference: European Respiratory Journal
- Année / Year: 2012
- PMID: 21659409
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/21659409
Lung cancer in never smokers - A review
- Journal / Conference: European Journal of Cancer
- Année / Year: 2012
- PMID: 22464348
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/22464348
High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non-Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway
- Journal / Conference: Molecular Cancer Therapeutics
- Année / Year: 2012
- PMID: 22411898
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/22411898
An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial
- Etude concernée: IFCT-0002
- Journal / Conference: Clinical Cancer Research
- Année / Year: 2012
- PMID: 22434665
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/22434665
Professional Exposure to Goats Increases the Risk of Pneumonic-Type Lung Adenocarcinoma: Results of the IFCT-0504-Epidemio Study
- Etude concernée: IFCT-0504
- Journal / Conference: PLOS One
- Année / Year: 2012
- PMID: 22655078
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/22655078
Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials.
- Journal / Conference: Journal of Thoracic Oncology
- Année / Year: 2012
- PMID: 22722786
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/22722786
Chemotherapy Effectiveness After First-Line Gefitinib Treatment for Advanced Lepidic Predominant Adenocarcinoma (Formerly Advanced Bronchioloalveolar Carcinoma): Exploratory Analysis of the IFCT-0401 Trial
- Etude concernée: 0401-EPIDEMIO
- Journal / Conference: Journal of Clinical Oncology
- Année / Year: 2012
- PMID: 22767177
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/22767177
Randomized, Phase III Study (IFCT-GFPC 0502) of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non-Small-Cell Lung Cancer
- Etude concernée: IFCT-0502
- Journal / Conference: Journal of Clinical Oncology
- Année / Year: 2012
- PMID: 22949150
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/22949150
Therapeutic options in older patients with metastatic non-small cell lung cancer
- Journal / Conference: Therapeutic Advances in Medical Oncology
- Année / Year: 2012
- PMID: 22942907
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/22942907
Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Project-Part 2)
- Etude concernée: ERMETIC
- Journal / Conference: Annals of Oncology
- Année / Year: 2012
- PMID: 22982650
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/22982650
From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe d’Oncologie de langue française
- Journal / Conference: Annals of Oncology
- Année / Year: 2013
- PMID: 23136229
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/23136229
From the NLST randomized trial to the clinic: How should we implement individual lung cancer screening in clinical practice?
- Journal / Conference: Revue des Maladies Respiratoires
- Année / Year: 2013
- PMID: 23318184
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/23318184
Efficacy of Pemetrexed as Second-Line Therapy in Advanced NSCLC after Either Treatment-Free Interval or Maintenance Therapy with Gemcitabine or Erlotinib in IFCT-GFPC 05-02 Phase III Study
- Etude concernée: IFCT-0502
- Journal / Conference: Journal of Thoracic Oncology
- Année / Year: 2013
- PMID: 23591160
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/23591160
A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial)
- Etude concernée: IFCT-0002
- Journal / Conference: European Journal of Cancer
- Année / Year: 2013
- PMID: 23735703
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/23735703
Lung cancer in never smokers: A French national cohort (BioCAST/IFCT-1002)
- Etude concernée: IFCT-1002
- Journal / Conference: Revue des Maladies Respiratoires
- Année / Year: 2013
- PMID: 24034464
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/24034464
The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism
- Journal / Conference: International Journal of Cancer
- Année / Year: 2013
- PMID: 24374738
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/24374738
Reply to letter EJC-D-13-01186
- Journal / Conference: European Journal of Cancer
- Année / Year: 2013
Second-line therapy in elderly patients with advanced non-small cell lung carcinoma: analysis of the IFCT-0501 Phase III study comparing single-agent therapy to carboplatin-based doublet therapy with fixed second-line erlotinib therapy.
- Etude concernée: IFCT-0501
- Journal / Conference: European Respiratory Journal
- Année / Year: 2014
A Multicenter Blinded Study Evaluating EGFR and KRAS Mutation Testing Methods in the Clinical Non-Small Cell Lung Cancer Setting-IFCT/ERMETIC2 Project Part 1: Comparison of Testing Methods in 20 French Molecular Genetic National Cancer Institute Platforms
- Journal / Conference: The Journal of Molecular Diagnostics
- Année / Year: 2014
- PMID: 24183959
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/24183959
Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.
- Journal / Conference: Annals of Oncology
- Année / Year: 2014
- PMID: 24285021
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/24285021
Individual lung cancer screening in practice. Perspectives on the propositions from the multidisciplinary group of the Intergroupe francophone de cancérologie thoracique, the Société d'imagerie thoracique and the Groupe d'oncologie de langue française
- Journal / Conference: Revue des Maladies Respiratoires
- Année / Year: 2014
- PMID: 24461451
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/24461451
Lung cancer and HIV infection
- Etude concernée: IFCT-1001
- Journal / Conference: Revue des Maladies Respiratoires
- Année / Year: 2014
- PMID: 24602680
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/24602680
Customized Adjuvant Phase II Trial in Patients With Non-Small-Cell Lung Cancer: IFCT-0801 TASTE
- Etude concernée: IFCT-0801
- Journal / Conference: Journal of Clinical Oncology
- Année / Year: 2014
- PMID: 24638013
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/24638013
Estimating overdiagnosis in lung cancer screening
- Journal / Conference: JAMA internal Medicine
- Année / Year: 2014
- PMID: 25003882
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/25003882
Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002
- Etude concernée: IFCT-1002
- Journal / Conference: Clinical Cancer Research
- Année / Year: 2014
- PMID: 25013125
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/25013125
RhoB Determines Tumor Aggressiveness in a Murine EGFRL858R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer
- Journal / Conference: Clinical Cancer Research
- Année / Year: 2014
- PMID: 25511923
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/25320360
Phase II randomized trial of afatinib with or without cetuximab as first-line treatment for EGFR mutated non-small cell lung cancer (NSCLC) patients (IFCT-1503 ACE-Lung)
- Etude concernée: IFCT-1503
- Journal / Conference: ASCO
- Année / Year: 2019
- PMID: Poster
Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study
- Etude concernée: IFCT-0502
- Journal / Conference: BMC Cancer
- Année / Year: 2014
- PMID: 25511923
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/25511923
BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers
- Journal / Conference: European Respiratory Journal
- Année / Year: 2015
- PMID: 25657019
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/25657019
- PDF: 2015_-_ERJ_-_BioCAST_full.pdf
Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301)
- Etude concernée: IFCT-0301
- Journal / Conference: Journal of Geriatric Oncology
- Année / Year: 2015
- PMID: 25698450
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/25698450
- PDF: JGO_2015_-_IFCT_0301.pdf
No impact of passive smoke on the somatic profile of lung cancers in never-smokers
- Journal / Conference: European Respiratory Journal
- Année / Year: 2015
- PMID: 25745045
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/25745045
- PDF: 2015_-_ERJ_-_Passive_smoking_Biocast.pdf
Randomized Phase II-III Study of Bevacizumab in Combination with Chemotherapy in Previously Untreated Extensive Small-Cell Lung Cancer: Results from the IFCT-0802 Trial
- Etude concernée: IFCT-0802
- Journal / Conference: Annals of Oncology
- Année / Year: 2015
- PMID: 25688059
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/25688059
- PDF: IFCT0802.AO.05.2015.pdf
Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study)
- Etude concernée: IFCT-0702
- Journal / Conference: Lung Cancer
- Année / Year: 2015
- PMID: 26059274
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/26059274
- PDF: 0702_-_LUNG4858.pdf
Reply to the letter to the editor 'Flaws in the trial design of IFCT-0802' by Gyawali et al
- Etude concernée: IFCT-0802
- Journal / Conference: Annals of Oncology
- Année / Year: 2015
- PMID: 26254441
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/26254441
- PDF: pdf-annals_oncol2015.pdf
Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504
- Etude concernée: IFCT-0504
- Journal / Conference: European Respiratory Journal
- Année / Year: 2015
- PMID: 26381515
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/26381515
- PDF: Cadranel_IFCT_0504_ERJ.pdf
Reply to the letter to the editor 'Prevalence of rare EGFR mutations in non-small cell lung cancer: a multicenter study on 3856 Polish Caucasian patients' by Krawczyk et al.
- Journal / Conference: Annals of Oncology
- Année / Year: 2015
- PMID: 26658890
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/26658890
Pathological complete response: A predictive survival factor after neoadjuvant chemotherapy in lung cancer
- Etude concernée: IFCT-0002
- Journal / Conference: Bulletin du cancer
- Année / Year: 2015
- PMID: 26682626
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/26682626
Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients.
- Journal / Conference: European Journal of Cancer
- Année / Year: 2016
- PMID: 26682871
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/26682871
- PDF: Prognostic_value_of_health_related_quality_of_life_-_EJC.pdf
Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 0201
- Journal / Conference: European Journal of Cancer
- Année / Year: 2016
- PMID: 26689864
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/26689864
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
- Etude concernée: BF
- Journal / Conference: The Lancet
- Année / Year: 2016
- PMID: 26777916
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/26777916
- PDF: Routine_molecular_profiling_of_patients_with_advabced_non_small_cell_lung_cancer_Lancet.pdf
Sensitivity to chemotherapy/tyrosine kinase inhibitors of mucinous lepidic adenocarcinoma should be tested in a phase III trial?
- Journal / Conference: European Respiratory Journal
- Année / Year: 2016
- PMID: 27246084
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/27246084
- PDF: Sensitivity_to_chemoterapy._Cadranel.ERJ.2016.pdf
Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy.
- Journal / Conference: European Respiratory Journal
- Année / Year: 2016
- PMID: 27338193
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/27338193
- PDF: Health_related_quality_of_life_-_ERJ.pdf
Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network
- Etude concernée: IFCT-1104
- Journal / Conference: Lung Cancer
- Année / Year: 2016
- PMID: 27237035
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/27237035
Lung Cancer Screening with Chest Computed Tomography in People Living with HIV. A Review by the Multidisciplinary CANCERVIH Working Group
- Journal / Conference: Journal of Thoracic Oncology
- Année / Year: 2016
- PMID: 27449803
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/27449803
- PDF: Lunc_cancer_screening_-_JTO.pdf
MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial.
- Etude concernée: IFCT-0002
- Journal / Conference: Oncotarget
- Année / Year: 2016
- PMID: 28008145
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/28008145
- PDF: MSH2_-_IFCT_00002_-_oncotarget-08-4313.pdf
Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France
- Etude concernée: BF
- Journal / Conference: Journal of Thoracic Oncology
- Année / Year: 2017
- PMID: 28189832
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/28189832
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial
- Etude concernée: IFCT-0703
- Journal / Conference: Annals of Oncology
- Année / Year: 2017
- PMID: 28327934
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/28327934
- PDF: Pazo.Adj.AO.03.2017.pdf
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK) : a French nationwide cohort retrospective study
- Etude concernée: IFCT-1302
- Journal / Conference: Oncotarget
- Année / Year: 2017
- PMID: 28423535
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/28423535
- PDF: Overall_survival_with_crizotinib_Oncotarget.pdf
Clinical research activity of the French cancer cooperative network: Overview and perspectives
- Journal / Conference: Bulletin du cancer
- Année / Year: 2017
- PMID: 28688747
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/28688747
- PDF: Article_GCO_Bulletin_du_Cancer.pdf
Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients
- Journal / Conference: ESMO open
- Année / Year: 2017
- PMID: 29021919
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/29021919
- PDF: Safeguarding_ESMO_open.pdf
EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice
- Journal / Conference: European Respiratory Journal
- Année / Year: 2017
- PMID: 28798090
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/28798090
- PDF: TKIvsCTWildType.ERJ.08.2017.pdf
Current knowledge on perioperative treatments of non-small cell lung carcinomas
- Journal / Conference: Revue des Maladies Respiratoires
- Année / Year: 2017
- PMID: 28709816
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/28709816
Clinical and molecular characteristics of non-small cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program
- Etude concernée: BF
- Journal / Conference: Annals of Oncology
- Année / Year: 2017
- PMID: 28945865
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/28945865
- PDF: BMF.EGFR.Leduc.AO.11.2017.pdf
Association between lung cancer somatic mutations and occupational exposure in never-smokers
- Journal / Conference: European Respiratory Journal
- Année / Year: 2017
- PMID: 29074543
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/29074543
- PDF: Expo.Prof.Mut.ERJ.10.2017.pdf
Structuring the French Thoracic Oncology over the Last 20 Years
- Journal / Conference: Revue des Maladies Respiratoires
- Année / Year: 2017
- PMID: 29033204
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/29033204
Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer)
- Etude concernée: IFCT-1102
- Journal / Conference: ESMO open
- Année / Year: 2018
- PMID: 30094074
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/30094074
- PDF: IFCT-1102_Bucil.pdf
Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study
- Etude concernée: PREDICT.amm
- Journal / Conference: European Respiratory Journal
- Année / Year: 2018
- PMID: 29545318
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/29545318
- PDF: IFCT-PREDICT.amm.pdf
Systemic therapy in advanced thymic epithelial tumors: Insights from the RYTHMIC prospective cohort
- Etude concernée: IFCT-1104
- Journal / Conference: Journal of Thoracic Oncology
- Année / Year: 2018
- PMID: 30138763
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/30138763
IoNESCO trial: Immune neoajuvant therapy in early stage non-small cell lung cancer
- Journal / Conference: Revue des Maladies Respiratoires
- Année / Year: 2018
- PMID: 30243521
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/30243521
Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2)
- Journal / Conference: Clinical Lung Cancer
- Année / Year: 2018
- PMID: 30679079
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/30679079
- PDF: ERMETIC.CLC.02.2019pdf.pdf
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
- Etude concernée: IFCT-1501
- Journal / Conference: The Lancet Oncology
- Année / Year: 2019
- PMID: 30660609
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/30660609
- PDF: MAPS2_Lancet.pdf
A Randomized Non-Comparative Phase 2 Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients with Small Cell Lung Cancer: Results from the IFCT 1603 Trial
- Etude concernée: IFCT-1603
- Journal / Conference: Journal of Thoracic Oncology
- Année / Year: 2019
- PMID: 30664989
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/30664989
MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial
- Etude concernée: MAPS
- Journal / Conference: British Journal of cancer
- Année / Year: 2019
- PMID: 30739911
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/30739911
- PDF: MST1hippo_in_MAPS_BJC_2019.pdf
Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study
- Etude concernée: BF
- Journal / Conference: European Journal of Cancer
- Année / Year: 2019
- PMID: 31181537
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/31181537
Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort
- Etude concernée: MAPS
- Journal / Conference: Clinical Lung Cancer
- Année / Year: 2019
- PMID: 31279641
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/31279641
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial
- Journal / Conference: Annals of Oncology
- Année / Year: 2019
- PMID: 31584608
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/31584608
Brief report : High MET overexpression does not predict the presence of MET exon 14 splice mutations in NSCLC : results from the IFCT Predict.amm study
- Etude concernée: PREDICT.amm
- Journal / Conference: Journal of Thoracic Oncology
- Année / Year: 2019
- PMID: 31605799
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/31605799
Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial.
- Etude concernée: IFCT-0002
- Journal / Conference: Cancers
- Année / Year: 2019
- PMID: 31766357
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/31766357
Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the Fren
- Etude concernée: BF
- Journal / Conference: Lung Cancer
- Année / Year: 2019
- PMID: 31841714
- Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/31841714
Risk factors for COVID-19 severity and mortality among solid cancer patients and its impact on anticancer treatment: a nationwide cohort study (GCO-002 CACOVID-19)
- Etude concernée: GCO-002
- Journal / Conference: European Journal of Cancer
- Année / Year: 2020
- PMID: 33129039
- Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/33129039/
- PDF: CACOVID_EJC_Octobre20.pdf
Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations
- Journal / Conference: Annals of Oncology
- Année / Year: 2020
- PMID: 31959346
- Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/31959346/
Randomized phase II trial evaluating treatment with EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial
- Etude concernée: IFCT-1003
- Journal / Conference: Clinical Cancer Research
- Année / Year: 2020
- PMID: 32144133
- Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/32144133/
- PDF: MazieresLADIE_CCR2020.pdf
Somatic profile in lung cancers is associated to reproductive factors in never-smokers women: Results from the IFCT-1002 BioCAST study
- Etude concernée: IFCT-1002
- Journal / Conference: Respiratory Medicine and Research
- Année / Year: 2020
- PMID: 32416585
- Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/32416585/
Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study
- Etude concernée: IFCT-1103
- Journal / Conference: European Journal of Cancer
- Année / Year: 2020
- PMID: 32276179
- Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/32276179/
- PDF: IFCT-1103_ULTIMATE_EJC_Publication.pdf
Inequity in access to personalized medicine in France: Evidences from analysis of geo variations in the access to molecular profiling among advanced non-small-cell lung cancer patients: Results from the IFCT Biomarkers France Study
- Etude concernée: BF
- Journal / Conference: PLOS One
- Année / Year: 2020
- PMID: 32609781
- Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/32609781/
- PDF: Inequity_biomarkers.pdf
First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial
- Etude concernée: IFCT-1001
- Journal / Conference: European Respiratory Journal
- Année / Year: 2020
- PMID: 32444410
- Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/32444410/
- PDF: ERJ-02066-2019_CHIVA_final.pdf
Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes
- Etude concernée: BF
- Journal / Conference: Journal of Thoracic Oncology
- Année / Year: 2020
- PDF: KRAS_JTO.pdf
Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial
- Etude concernée: IFCT-1201
- Journal / Conference: European Journal of Cancer
- Année / Year: 2020
- PMID: 32898792
- Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/32898792/
- PDF: IFCT-1201_MODEL_publication_EJC.pdf
Lorlatinib for advanced ALK and ROS1+ non-small cell lung cancer (NSCLC): Efficacy and treatment sequences in the IFCT-1803 LORLATU expanded access program (EAP) cohort
- Etude concernée: IFCT-1803
- Journal / Conference: ASCO
- Année / Year: 2020
- PMID: Poster
- Lien vers la publication: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.9615